Navigation Links
Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
Date:9/30/2013

tatements are usually (but not always) identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of risks and uncertainties including clinical trial enrollment and results, regulatory approval requirements, unexpected expenditures and costs, unexpected results or delays in development and regulatory review, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 7, 2013. Halozyme does not undertake to update these forward-looking statements.

References
1. Pancreatic Cancer Treatment, National Cancer Institute, http://www.cancer.gov/cancertopics/pdq/treatment/pancreatic/HealthProfessional/page1/AllPages.Accessed September 19, 2013
2. American Cancer Society, Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013.
3. Pancreatic Cancer, American Cancer Society,http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-key-statistics. Accessed September 19, 2013.

Investor Contact:
David Ramsay
Halozyme Therapeutics
858-704-8260
ir@halozyme.com

Media Contact:
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
2. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
3. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
4. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
5. Halozyme Reports Second Quarter 2013 Financial Results
6. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
7. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
8. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
9. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
10. Halozyme Reports First Quarter 2013 Financial Results
11. Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... PITTSBURGH , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage ... at the Australian and New Zealand Forensic Science ... Forensic Sciences in Adelaide, Australia ... discussion concerning the advancements that hyperspectral imaging can ... Jeffrey Beckstead , Director of Product Development ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... 2014  Pacific Medical Data Solutions is excited to ... . The main website, along with the site,s blog, ... services and content relevant to the medical billing industry. ... viewers can now better understand how PMDS products help ... create a more visible platform about medical billing best ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4PMDS Announces New Website 2
... AMSTERDAM, April 18, 2012  Leading events organiser UBM Live ... the global UBM Pharma Portfolio, CPhI Southeast Asia (SEA) 2012. ... International Expo in Indonesia, CPhI SEA is the first trade ... the pharmaceutical ingredient sector in the ASEAN region. ...
... -   Retrospective sub-analyses from ADVANCE, ... European Association for the Study of the Liver (EASL) 2012 ... new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses ... the Study of the Liver (EASL) in Barcelona.  The data ...
Cached Medicine Technology:Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 2INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 3INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 4INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 5INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 6INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1 Chronic HCV 7
(Date:8/29/2014)... 29, 2014 Dr. Parsa Mohebi M.D. has ... hair loss achieve great results in hair transplantation. One ... Transplant , an FUE method that harvests facial hair for ... method lets patients whose hair loss classification is 5 and ... is a great alternative for those advanced hair loss patients ...
(Date:8/29/2014)... Highly regarded audiologist , Dr. Mary Ann Larkin has ... four reports are titled:, , Revealing the Truth ... , The Top 5 Things You Should Know Before ... in Children , Dr. Mary Anne Larkin choose to ... confusion and misinformation about each them. The reports are available ...
(Date:8/29/2014)... 2014 Pursuing its deepest desires to ... unveil a stunning new design that promises to redefine ... highly notable surrogacy platform has witnessed a 42 percent ... visitors a month, the FindSurrogateMother.com community is formed by ... common goal — the precious gift of life. , ...
(Date:8/29/2014)... 29, 2014 (HealthDay News) -- If you have bunions, taking ... treatment later, an expert says. A bunion is a ... when bone or tissue moves out of place and extends ... can cause debilitating pain and may require surgery to correct, ... Medical Center in Freehold, N.J. To prevent bunions, avoid ...
(Date:8/29/2014)... August 29, 2014 - Despite US Preventive Services ... are many barriers, several of which may be ameliorated ... researchers at NYU Langone Medical Center published online August ... Medicine ( JGIM ). , David Levine, MD, ... Internal Medicine at NYU Langone, and colleagues found that ...
Breaking Medicine News(10 mins):Health News:Advanced Hair Loss Patients Can Now Qualify for Hair Transplants Using Facial Donor Hair 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 2Health News:FindSurrogateMother.com Set to Unveil Stunning New Design as Member Sign-ups Increase by 42% since January 3Health News:Take Steps to Control Bunions 2Health News:Options for weight loss your primary care doctor might not know about 2
... Than 1,500 YMCAs Get Their Communities Moving During Week-Long Event; ... YMCAs Aim to Keep Communities Active Year-Round, WASHINGTON, ... logged during "America On the Move Week with the YMCA" ... More than 1,500 YMCAs nationwide reached out to their ...
... With an eye on curing diabetes, scientists at Washington ... transplanted embryonic pig pancreatic cells destined to produce insulin ... for risky immune suppression drugs that prevent rejection. , ... earliest stages of developing into pancreatic tissues. Within several ...
... it instead of traditional immune globulin injection , , THURSDAY, ... hepatitis A with the hepatitis A vaccine is as ... of immune globulin, a new study found. , Based ... and Prevention,s Advisory Committee on Immunization Practices now recommends ...
... Union Urges Congress to Enact HR 1174 (Murphy) ... WASHINGTON, Oct. 18 A new study that,estimates ... virulent,antibiotic-resistant infection acquired mostly in the hospital underscores,the ... patient infection,rates, according to Consumers Union, the nonprofit ...
... device evaluated in cadaver by leading spine ... ... CoreSpine Technologies LLC, an,emerging spinal device company located in Minneapolis, Minnesota ... first product in development is a complete nucleus removal,device that seeks ...
... Conseco, Inc. (NYSE:,CNO) will report results for the ... 31, 2007. The company will host a conference call ... November 1, 2007. The web cast of the ... the company,s website as follows:, http://investor.conseco.com . Listeners should ...
Cached Medicine News:Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 2Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 3Health News:YMCA's Activate America(R) Motivates More Than 1.3 Million People to Take 8 Billion Steps Toward a Healthier Lifestyle During 'America On the Move Week with the YMCA' 4Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 2Health News:Cross-species transplant in rhesus macaques is step toward diabetes cure for humans 3Health News:Hepatitis A Vaccine Best Bet to Treat Virus 2Health News:Hepatitis A Vaccine Best Bet to Treat Virus 3Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 2Health News:Alarming MRSA Infection Rates Underscore Need for Public Reporting of Hospital-Acquired Infections 3Health News:Initial Evaluation of New Nucleus Removal Device Provides Promising Results 2
... standard trial frames. They are made of optical quality ... box. There are two sets available providing a full ... is that a patient can wear the prism with ... the patient to adapt to the use of the ...
... C Dermatome - reaching a new evolutionary plateau. ... to operate in the pulse mode, or to ... entire instrument and hose assembly is autoclavable and ... 2-, 3-, or 4-inch widths. Simply select the ...
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator (Fenzl), blunt tip angled 45, 12.0 mm from end, fits 0.20 mm diameter holes and larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge ind...
Medicine Products: